Drug recall · May 30, 2018
Loxapine Capsules recall
Why: GMP Deviations: a recent FDA inspection of the manufacturing site revealed multiple cGMP violations that would place Loxapine at risk for cross contamination
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Loxapine Capsules, USP 50 mg, packaged in 100 Unit Dose capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC 51079-903-20.
- Lots / codes
Lot #: 3092310, Exp. 03/2019
- Quantity
- 1,152 blister cards of 100 capsules each
- Company
- Mylan Institutional, Inc. (d.b.a. UDL Laboratories), Rockford, IL
- Distribution
- Nationwide in the U.S.
- Initiated
- May 1, 2018 · Voluntary: Firm initiated
- Classified
- May 22, 2018
- Reported
- May 30, 2018
- Ended
- March 10, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Loxapine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.